Assyro AI

FDA Orange Book · active-ingredient family

Amifostine

Amifostine is approved as 1 brand and 2 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:ETHYOL · NDA 020221

1

Brand (NDA)

2

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
ETHYOLRLD×2LEGACY PHARMANDA 020221Dec 08, 1995

Generic (ANDA) products (2)

ProductApplicantApplicationTEApproved
AMIFOSTINEEUGIA PHARMA SPECLTSANDA 204363Jul 17, 2017
AMIFOSTINESUN PHARMANDA 077126Mar 14, 2008

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Amifostine — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.